Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications

Clinical and Experimental Pharmacology and Physiology

Volumn 25, Issue 2, 1998, Pages 79-87

  Donnelly, Richard ^a,b   Qu, Xianqin ^a  

^a University of Sydney   (Australia)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Insulin resistance; Non esterified free fatty acids; Non insulin dependent diabetes mellitus; Obesity; Protein kinase C

Indexed keywords

6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ANTILIPEMIC AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FATTY ACID; GLUCOSE; PROTEIN KINASE C; RUBOXISTAURIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ADIPOSE TISSUE; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; SKELETAL MUSCLE;

EID: 0031883627     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1998.tb02181.x     Document Type: Review

References (85)

1. Zimmet P, McCarty D. The NIDDM epidemic: Global estimates and projections. A look into the crystal ball. Int. Diabet. Fed. Bull. 1995; 40: 8-16.
2. Harris MI, Klein R, Welborn TA, Kneiman MV. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15: 815-9.
3. UK Prospective Diabetes Study Group 6. Complications in newly diagnosed type II diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 1990; 13: 1-11.
4. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed NIDDM followed for three years. BMJ 1995; 310: 83-8.
5. DeFronzo RA. Pathogenesis of type II (non-insulin-dependent) diabetes mellitus: A balanced overview. Diabetologia 1992; 35: 389-97.
6. Moller DE, Flier JS. Insulin resistance: Mechanisms, syndromes and implications. N. Engl. J. Med. 1991; 325: 938-48.
7. Azhar S, Reaven GM. Characterization of insulin receptor kinase activity and autophosphorylation in different skeletal muscle types. Am. J. Physiol. 1991; 260: E1-7.
8. Reed MJ, Mondon C, Reaven GM. Why does insulin resistance develop during maturation? J. Gerontol. 1993; 48: B139-44.
9. Considine RV, Caro JF. Protein kinase C: Mediator or inhibitor of insulin action. J. Cell. Biochem. 1993; 52: 8-13.
10. Boggs KP, Farese RY, Buse MG. Insulin administration in vivo increases 1,2-diacylglycerol in rat skeletal muscle. Endocrinology 1991; 128: 636-8.
11. Bollag GB, Roth RA, Beaudoin J, Mochi-Rosen D, Koshland DE. PKC directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc. Natl Acad. Sci. USA 1986; 83: 5822-4.
12. Blackmore PF, Strickland WG, Exton JH. Phosphorylation of glycogen synthase by protein kinase C. Biochem. J. 1986; 237: 235-42.
13. Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of PKC isoenzymes α, β, γ and ∈ in cells overexpressing the insulin receptor. J. Biol. Chem. 1993; 268: 6338-47.
14. Ishizuka T, Yamamoto M, Kajita K et al. Differential effect of aging on PKC activity in rat adipocytes and soleus muscle. Metabolism 1993; 42: 420-5.
15. Cooper DR, Watson JE, Dao ML. Decreased expression of PKC-α, β and ∈ in soleus muscle of Zucker obese (fa/fa) rats. Endocrinology 1993; 133: 2241-7.
16. Heydrick SJ, Ruderman NS, Kurowski TG, Adams HB, Chen KS. Enhanced stimulation of DAG and lipid synthesis by insulin in denervated muscle: Altered PKC activity and possible link to insulin resistance. Diabetes 1991; 40: 1707-11.
17. Shmueli E, Alberti KGM, Record CO. Diacylglycerol/protein kinase C signalling: A mechanism for insulin resistance? J. Intern. Med. 1993; 234: 397-400.
18. Osada S-I, Mizuno K, Saido TC, Suzuki K, Kuroki T, Ohno O. A new member of the protein kinase C family, PKC-θ, predominantly expressed in skeletal muscle. Mol. Cell Biol. 1992; 12: 3930-8.
19. Chang JD, Xu Y, Raychowdhury MK, Ware JA. Molecular cloning and expression of a cDNA encoding a novel isozyme of protein kinase C (PKC-θ). J. Biol. Chem. 1993; 268: 14 208-14.
20. Donnelly R, Reed MJ, Azhar S, Reaven GM. Expression of the major isoenzyme of PKC in skeletal muscle, PKC-θ, varies with fibre-type composition and in response to fructose-induced insulin resistance. Endocrinology 1994; 135: 2369-74.
21. Donnelly R, Chang H, Reaven GM. Tissue-dependent activation of protein kinase C in fructose-induced insulin resistance. Endocrine 1995; 3: 129-33.
22. Vikman H-L, Kaarinen JM, Tuominer RK, Ohisalo JJ. A possible role for protein kinase C in the regulatory differences between intra-abdominal and subcutaneous human adipose tissue. Clin. Sci. 1993; 85: 265-8.
23. 1. FEBS Lett. 1988; 243: 77-82.
24. Schmitz-Peiffer C, Browne CL, Oakes ND et al. Alterations in the expression and cellular localization of protein kinase C isozymes ∈ and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997; 46: 169-78.
25. Qu X, Donnelly R. Is insulin resistance in the spontaneously hypertensive rat related to changes in protein kinase C in skeletal muscle? Am. J. Hypertens. 1997; 10: 1053-7.
26. Rao RH. Insulin resistance in spontaneously hypertensive rats. Diabetes 1993; 42: 1364-71.
27. Hulman S, Falkner B, Freyvogel N. Insulin resistance in the conscious spontaneously hypertensive rat: Euglycemic hyperinsulinemic clamp study. Metabolism 1993; 42: 14-18.
28. Filippis A, Clark S, Proietto J. Increased flux through the hexosamine biosynthesis pathway inhibits glucose transport acutely by activation of PKC. Biochem. J. 1997; 324: 981-5.
29. 3-adrenergic receptor. Science 1989; 245: 1118-21.
30. 3-adrenoceptor: the search for a physiological function. Trends Pharmacol. Sci. 1994; 15: 3-7.
31. 3-adrenergic receptor: A cause and cure of obesity? N. Engl. J. Med. 1995; 333: 382-3.
32. Muzzin P, Revelli J-P, Kuhne F et al. An adipose tissue-specific β-adrenergic receptor: Molecular cloning and down-regulation in obesity. J. Biol. Chem. 1991; 266: 24 053-8.
33. Susulic S, Frederich RC, Lawitts JA et al. Targeted disruption of the beta-3 adrenergic receptor gene. J. Biol. Chem. 1995; 270: 29 483-92.
34. 3-adrenoceptors in obesity. J. Clin. Invest. 1995; 95: 1109-16.
35. Yamauchi T, Tobe K, Tamemoto H et al. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, IRS-1-deficient mice. Mol. Cell Biol. 1996; 16: 3074-84.
36. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse ob gene and its human homologue. Nature 1994; 372: 425-32.
37. Hotamiegil GS, Shargill NS, Spiegelman BM. Adipose tissue expression of tumour necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
38. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N. Engl. J. Med. 1995; 333: 352-4.
39. 3-adrenergic receptor gene. N. Engl. J. Med. 1995; 333: 343-7.
40. 3-adrenoceptor gene with features of the insulin resistance syndrome in Finns. N. Engl. J. Med. 1995; 333: 348-51.
41. Schalin-Jantti C, Nikula-Ijas P, Huang X et al. Polymorphism of the glycogen synthase gene in hypertensive and normotensive subjects. Hypertension 1996; 27: 67-71.
42. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocrinol. Rev. 1995; 16: 117-42.
43. Maddux BA, Sbraccia P, Kumakura L et al. Membrane glycoprotein PC-1 and insulin resistance in NIDDM. Nature 1995; 373: 448-51.
44. 3-AR: How structure elucidates function. Annu. Rev. Pharmacol. Toxicol. 1992; 32: 167-83.
45. 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem. Biophys. Res. Commun. 1995; 215: 555-60.
46. 3-adrenergic receptor with NIDDM and body weight gain. Diabetologia 1996; 39: 349-52.
47. 3-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Diabetes 1996; 45: 1358-63.
48. 3-adrenoceptor gene polymorphism (Trp64Arg) in obese diabetic and non-diabetic subjects. Clin. Exp. Pharmacol. Physiol. 1997; 24: 733-5.
49. Li LS, Lonnqvist F, Luthman H, Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta3-adrenoceptor gene in normal weight and obese subjects. Diabetologia 1996; 39: 857-60.
50. Araki E, Lipes MA, Patti ME et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372: 186-90.
51. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in IRS-1 causes impaired insulin signaling. Evidence from transfection studies. J. Clin. Invest. 1996; 97: 2569-75.
52. DCCT Research Group. The diabetes control and complications trial. N. Engl. J. Med. 1993; 329: 683-9.
53. Porte D, Schwartz MW. Diabetes complications: Why is glucose potentially toxic. Science 1996; 272: 699-700.
54. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacyglycerol-protein kinase C in diabetes and hypergalactosaemia. Diabetes 1994; 43: 1122-9.
55. King GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann. Med. 1996; 28: 427-32.
56. King GL, Shiba T, Oliver J, Inoguchi T, Bursell S-E. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu. Rev. Med. 1994; 45: 179-88.
57. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats. Differential reversibility to glycaemic control by islet transplantation. Proc. Natl Acad. Sci. USA 1992; 89: 11 059-63.
58. Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na,K-adenosine triphosphatase by hyperglycaemia involving activation of PKC and cytosolic phospholipase A2. J. Clin. Invest. 1995; 96: 733-40.
59. Kunisaki M, Bursell S-E, Clermont AC et al. Vitamin E treatment prevents diabetes-induced abnormal retinal blood flow via the DAG-PKC pathway. Am. J. Physiol. 1995; 269: E239-46.
60. Kunisaki M, Bursell S-E, Umeda F, Nawata H, King GL. Normalization of DAG-PKC activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994; 43: 1372-7.
61. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves Beta-cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest. 1997; 100: 530-7.
62. Fujiwara T, Yoshioka S, Yoshioka T et al. Characterization of a new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-58.
63. Fujiwara T, Wada M, Fukuda K et al. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycaemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991; 40: 1213-18.
64. Ciaraldi TP, Gilmore A, Olefsky JM et al. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990; 39: 1056-62.
65. Suter SL, Nolan JJ, Wallace P et al. Metabolic effects of a new oral hypoglycaemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
66. Nolan JJ, Ludvik B, Beerdsen P et al. Improvement in glucose tolerance in obese subjects treated with troglitazone. N. Engl. J. Med. 1994; 331: 1188-93.
67. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a nonobese and normolipidaemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 1997; 46: 192-8.
68. Lambe KG, Tugwood JD. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. 1996; 239: 1-7.
69. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta and -gamma in the adult rat. Endocrinology 1996; 137: 354-66.
70. 3-adrenoceptors. Br. J. Clin. Pharmacol. 1996; 42: 291-300.
71. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose-fatty acid cycle. Its role in insulin insensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; i: 785-9.
72. Ebeling P, Koivisto VA. Non-esterified fatty acids regulate lipid and glucose oxidation and glycogen synthase activity. Diabetologia 1994; 37: 202-9.
73. Boden G, Chen X, Ruiz J, White J, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. 1994; 93: 2438-46.
74. Reaven GM, Chang H, Ho H, Jeng C-Y, Hoffman BB. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am. J. Physiol. 1988; 254: E23-30.
75. LaNoue KF, Martin LF. Abnormal A1 adenosine receptor function in genetic obesity. FASEB J. 1994; 8: 72-80.
76. Strong P, Anderson R, Coates J et al. Suppression of non-esterified fatty acids and triglycerides in experimental animals by the adenosine analogue GR79236. Clin. Sci. 1993; 84: 663-9.
77. Qu X, Cooney G, Donnelly R. Metabolic and haemodynamic effects of GR79236 in normal and fructose-fed rats. Eur. J. Pharmacol. 1997 (in press).
78. Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabetic Med. 1996; 13: S151-5.
79. Tamaoki T, Nomoto H, Takahashi I et al. Staurosporine: A potent inhibitor of phospholipid/Ca-dependent protein kinase. Biochem. Biophys. Res. Commun. 1986; 135: 397-402.
80. Hidaka H, Inagaki S, Kawamoto S, Sasaki Y. Isoquinoline-sulphonamides: Novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984; 23: 5036-41.
81. Van de werve G, Proietto J, Jeanrenaud B et al. Tumour-promoting phorbol esters increase basal and inhibit insulin-stimulated lipogenesis in rat adipocytes without decreasing insulin binding. Biochem. J. 1985; 225: 523-7.
82. Caro JF, Jenquin M, Long S. Effects of phorbol esters on insulin receptor function and insulin action in hepatocytes. Mol. Cell Biochem. 1992; 109: 115-18.
83. Gali RR, Pugazhenthi S, Khandelwal RL. Reciprocal effects of the protein kinase C inhibitors staurosporine and H-7 on the regulation of glycogen synthase and phosphorylase in the primary culture of hepatocytes. Metabolism 1993; 42: 1475-80.
84. Saltis J, Habberfield AD, Egan JJ et al. Role of protein kinase C in the regulation of glucose transport in the rat adipose cell. J. Biol. Chem. 1991; 266: 261-7.
85. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728-31.